Cefroxadine

DB11367

small molecule withdrawn

Deskripsi

Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.

Struktur Molekul 2D

Berat 365.4
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The serum half life is 0.9-1.1 h [A20320].
Volume Distribusi Volume of distrubution of 15 L [A20320].
Klirens (Clearance) The total body clearance is 340 mL/min and the renal clearance is 250 mL/min [A20320].

Absorpsi

Oral bioavailability of 90% A20320.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Primarily eliminated in the urine (80-96%) A20320.

Interaksi Obat

847 Data
Probenecid The serum concentration of Cefroxadine can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Cefroxadine is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefroxadine.
Tenofovir disoproxil Cefroxadine may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Cefroxadine.
Tenofovir Cefroxadine may increase the nephrotoxic activities of Tenofovir.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefroxadine.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefroxadine.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefroxadine.
Hydrochlorothiazide The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cefroxadine.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefroxadine.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefroxadine.
Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cefroxadine.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefroxadine.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefroxadine.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefroxadine.
Indomethacin The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefroxadine.
Cidofovir The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Cefroxadine.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefroxadine.
Ceftazidime The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Cefroxadine.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefroxadine.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefroxadine.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefroxadine.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefroxadine.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefroxadine.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefroxadine.
Cefotaxime The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefroxadine.
Tolmetin The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cefroxadine.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cefroxadine.
Piroxicam The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Cefroxadine.
Methotrexate The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Cefroxadine.
Cephalexin The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Cefroxadine.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cefroxadine.
Valaciclovir The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Cefroxadine.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cefroxadine.
Diclofenac The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cefroxadine.
Sulindac The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefroxadine.
Bacitracin The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cefroxadine.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefroxadine.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cefroxadine.
Flurbiprofen The risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Cefroxadine.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefroxadine.
Pentamidine The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cefroxadine.
Etodolac The risk or severity of nephrotoxicity can be increased when Etodolac is combined with Cefroxadine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cefroxadine.
Acyclovir The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Cefroxadine.
Naproxen The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefroxadine.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefroxadine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cefroxadine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Cefroxadine is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cefroxadine.
Cefaclor The risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Cefroxadine.
Diflunisal The risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Cefroxadine.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefroxadine.
Bumetanide The risk or severity of nephrotoxicity can be increased when Bumetanide is combined with Cefroxadine.
Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cefroxadine.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cefroxadine.
Meclofenamic acid The risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Cefroxadine.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefroxadine.
Carboplatin The risk or severity of nephrotoxicity can be increased when Carboplatin is combined with Cefroxadine.
Oxaprozin The risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Cefroxadine.
Ketoprofen The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Cefroxadine.
Balsalazide The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cefroxadine.
Ibuprofen The risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefroxadine.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefroxadine.
Atazanavir The risk or severity of nephrotoxicity can be increased when Atazanavir is combined with Cefroxadine.
Colistimethate The risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Cefroxadine.
Cefuroxime The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Cefroxadine.
Cefapirin The risk or severity of nephrotoxicity can be increased when Cefapirin is combined with Cefroxadine.
Cefadroxil The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Cefroxadine.
Cefprozil The risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Cefroxadine.
Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Cefroxadine.
Olsalazine The risk or severity of nephrotoxicity can be increased when Cefroxadine is combined with Olsalazine.
Lumiracoxib The risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Cefroxadine.
Cefamandole The risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Cefroxadine.
Cefazolin The risk or severity of nephrotoxicity can be increased when Cefazolin is combined with Cefroxadine.
Cefonicid The risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Cefroxadine.
Cefoperazone The risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Cefroxadine.
Cefotetan The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Cefroxadine.
Cefoxitin The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Cefroxadine.
Ceftizoxime The risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Cefroxadine.
Cefradine The risk or severity of nephrotoxicity can be increased when Cefradine is combined with Cefroxadine.
Magnesium salicylate The risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Cefroxadine.
Salsalate The risk or severity of nephrotoxicity can be increased when Salsalate is combined with Cefroxadine.
Choline magnesium trisalicylate The risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Cefroxadine.
Cefepime The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Cefroxadine.
Cefacetrile The risk or severity of nephrotoxicity can be increased when Cefacetrile is combined with Cefroxadine.
Ceftibuten The risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Cefroxadine.
Cefpodoxime The risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Cefroxadine.
Antrafenine The risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Cefroxadine.
Aminophenazone The risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Cefroxadine.
Antipyrine The risk or severity of nephrotoxicity can be increased when Antipyrine is combined with Cefroxadine.
Tiaprofenic acid The risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Cefroxadine.
Lopinavir The risk or severity of nephrotoxicity can be increased when Lopinavir is combined with Cefroxadine.
Etoricoxib The risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Cefroxadine.
Hydrolyzed Cephalothin The risk or severity of nephrotoxicity can be increased when Hydrolyzed Cephalothin is combined with Cefroxadine.
Cephalothin Group The risk or severity of nephrotoxicity can be increased when Cephalothin Group is combined with Cefroxadine.
Oxyphenbutazone The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Cefroxadine.
Latamoxef The risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Cefroxadine.
Nimesulide The risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefroxadine.

Target Protein

Penicillin-binding protein 1B mrcB

Referensi & Sumber

Synthesis reference: - R. Scartazzini, H. Bickel, DE 2331133; eidem, U.S. Patent 4,073,902 (1974, 1978 both to Ciba-Geigy). - Jump up ^ R. B. Woodward and H. Bickel, U.S. Patent 4,147,864 (1979); Chem. Abstr., 91, 74633J (1979).
Artikel (PubMed)
  • PMID: 6998373
    Yasuda K, Kurashige S, Mitsuhashi S: Cefroxadine (CGP-9000), an orally active cephalosporin. Antimicrob Agents Chemother. 1980 Jul;18(1):105-10.
  • PMID: 3319507
    Bergan T: Pharmacokinetic properties of the cephalosporins. Drugs. 1987;34 Suppl 2:89-104.
Textbook
  • ISBN: 9780071624428
    53. (2011). In Goodman and Gilman's the pharmacological basis of therapeutics, Pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Cefthan-DS — Novartis
  • Oraspor — Novartis

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul